Login / Signup

Association between Pre-Pregnancy BMI and Inflammatory Profile Trajectories during Pregnancy and Postpartum in Brazilian Women with Periodontitis: The IMPROVE Trial.

Danilo Dias SantanaGilberto KacPedro Paulo Teixeira Dos SantosThainá Castro da SilvaCamila BenaimPaula Guedes CocateMaria Beatriz Trindade de CastroBerit Lilienthal HeitmannAmanda Rodrigues Amorim Adegboye
Published in: International journal of environmental research and public health (2022)
This study aimed to explore the association between pre-pregnancy BMI and longitudinal changes in inflammatory markers from the second trimester of pregnancy to 6-8 weeks postpartum in women with periodontitis. This is a secondary exploratory analysis of 68 women who took part in a feasibility clinical trial in Rio de Janeiro, Brazil. Inflammatory markers included C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), and matrix metalloproteinase-9 (MMP-9) blood concentrations at 11-22 (T0) and 30-36 gestational weeks (T1), and 6-8 weeks postpartum (T3). Longitudinal generalised linear mixed-effects models were used to identify possible associations between pre-pregnancy BMI and changes in concentrations of inflammatory markers. Pre-pregnancy excess weight (β = 4.39; 95% CI, 2.12-6.65) was significantly associated with increased CRP levels from pregnancy to postpartum. There were no significant associations between pre-pregnancy BMI and longitudinal changes in IL-6, IL-10 and MMP-9. Our findings provide evidence that a higher pre-pregnancy BMI may lead to increases in CRP levels during pregnancy in women with periodontitis, irrespective of the severity of clinical periodontal parameters. Further studies need to investigate if predictors of changes in inflammatory markers can be used as prognostic factors for gestational outcomes.
Keyphrases
  • pregnancy outcomes
  • preterm birth
  • weight gain
  • body mass index
  • clinical trial
  • pregnant women
  • prognostic factors
  • gestational age
  • type diabetes
  • birth weight
  • phase iii
  • breast cancer risk
  • case control